PMID- 34823043
OWN - NLM
STAT- MEDLINE
DCOM- 20220621
LR  - 20221003
IS  - 2213-7173 (Electronic)
IS  - 2213-7165 (Linking)
VI  - 29
DP  - 2022 Jun
TI  - Novel beta-lactam/beta-lactamase inhibitor combinations versus alternative antibiotics 
      in adults with hospital-acquired pneumonia or ventilator-associated pneumonia: an 
      integrated analysis of three randomised controlled trials.
PG  - 398-404
LID - S2213-7165(21)00238-1 [pii]
LID - 10.1016/j.jgar.2021.09.013 [doi]
AB  - OBJECTIVES: This study assessed the efficacy and safety of novel 
      beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations in adult patients with 
      hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP). 
      METHODS: PubMed, Web of Science, the Cochrane Library, Ovid MEDLINE, Embase and 
      EBSCO databases were searched for randomised controlled trials (RCTs) published 
      before 13 September 2020. Only RCTs comparing the treatment efficacy of novel 
      BL/BLI combinations with other antibiotics for HAP/VAP in adult patients were 
      included in this integrated analysis. RESULTS: Three RCTs were included and no 
      significant difference in clinical cure rate of test of cure was observed between 
      the novel BL/BLI combinations and comparators [odds ratio (OR) = 1.01, 95% 
      confidence interval (CI) 0.81-1.27; I(2) = 35%]. The 28-day all-cause mortality 
      was 16.2% and 17.6% for patients receiving novel BL/BLI combinations and 
      comparators, respectively, and no significant difference was noted (OR = 0.90, 
      95% CI 0.69-1.16; I(2) = 11%). Compared with comparators, novel BL/BLI 
      combinations were associated with a similar microbiological response (OR = 1.06, 
      95% CI 0.73-1.54; I(2) = 64%) and a similar risk of adverse events (AEs) 
      [treatment-emergent AEs (TEAEs): OR = 1.04, 95% CI 0.83-1.30; I(2) = 0%; serious 
      AEs: OR = 1.14, 95% CI 0.79-1.63; I(2) = 68%; treatment discontinuation for TEAE: 
      OR = 0.90, 95% CI 0.62-1.31; I(2) = 11%). CONCLUSION: Clinical and 
      microbiological responses of novel BL/BLI combinations in the treatment of 
      HAP/VAP were similar to those of other available antibiotics. These combinations 
      also shared a similar safety profile to comparators.
CI  - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Zhuang, Huamei
AU  - Zhuang H
AD  - School of Pharmaceutical Sciences and Medical Technology, Putian University, 
      Putian 351100, China.
FAU - Lai, Chih-Cheng
AU  - Lai CC
AD  - Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan 
      Branch, Tainan, Taiwan.
FAU - Lan, Shao-Huan
AU  - Lan SH
AD  - School of Pharmaceutical Sciences and Medical Technology, Putian University, 
      Putian 351100, China.
FAU - Chang, Shen-Peng
AU  - Chang SP
AD  - Yijia Pharmacy, Tainan 70846, Taiwan.
FAU - Lu, Li-Chin
AU  - Lu LC
AD  - School of Management, Putian University, Putian 351100, China.
FAU - Hung, Shun-Hsing
AU  - Hung SH
AD  - Division of Urology, Department of Surgery, Chi-Mei Hospital, Chia Li, Tainan, 
      Taiwan. Electronic address: e197948@yahoo.com.tw.
FAU - Lin, Wei-Ting
AU  - Lin WT
AD  - Department of Orthopedics, Chi Mei Medical Center, Tainan 71004, Taiwan. 
      Electronic address: aapriliaa@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20211122
PL  - Netherlands
TA  - J Glob Antimicrob Resist
JT  - Journal of global antimicrobial resistance
JID - 101622459
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Lactams)
RN  - 0 (beta-Lactamase Inhibitors)
RN  - 0 (beta-Lactams)
SB  - IM
MH  - Adult
MH  - Anti-Bacterial Agents/adverse effects
MH  - Drug Combinations
MH  - Hospitals
MH  - Humans
MH  - Lactams/therapeutic use
MH  - *Pneumonia, Ventilator-Associated/drug therapy/microbiology
MH  - Randomized Controlled Trials as Topic
MH  - *beta-Lactamase Inhibitors/adverse effects
MH  - beta-Lactams/adverse effects
OTO - NOTNLM
OT  - Hospital-acquired pneumonia
OT  - Mortality
OT  - Novel beta-lactam/beta-lactamase inhibitor
OT  - Ventilator-associated pneumonia
COIS- Declaration of Competing Interest None declared.
EDAT- 2021/11/26 06:00
MHDA- 2022/06/22 06:00
CRDT- 2021/11/25 20:14
PHST- 2020/11/24 00:00 [received]
PHST- 2021/03/24 00:00 [revised]
PHST- 2021/09/23 00:00 [accepted]
PHST- 2021/11/26 06:00 [pubmed]
PHST- 2022/06/22 06:00 [medline]
PHST- 2021/11/25 20:14 [entrez]
AID - S2213-7165(21)00238-1 [pii]
AID - 10.1016/j.jgar.2021.09.013 [doi]
PST - ppublish
SO  - J Glob Antimicrob Resist. 2022 Jun;29:398-404. doi: 10.1016/j.jgar.2021.09.013. 
      Epub 2021 Nov 22.